Deutsche Bank’s Trevi Therapeutics TRVI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.54M Sell
107,271
-7,216
-6% -$124K ﹤0.01% 1947
2026
Q2
$2.14M Buy
114,487
+29,732
+35% +$432K ﹤0.01% 1871
2026
Q1
$1.01M Buy
84,755
+13,922
+20% +$156K ﹤0.01% 2175
2025
Q4
$887K Buy
70,833
+19,193
+37% +$222K ﹤0.01% 2247
2025
Q3
$473K Buy
51,640
+8,203
+19% +$61.5K ﹤0.01% 2571
2025
Q2
$238K Buy
43,437
+5,811
+15% +$36.2K ﹤0.01% 2865
2025
Q1
$237K Buy
37,626
+8,383
+29% +$40K ﹤0.01% 2877
2024
Q4
$120K Buy
29,243
+685
+2% +$2.19K ﹤0.01% 3242
2024
Q3
$95.4K Buy
28,558
+14,635
+105% +$43.5K ﹤0.01% 3233
2024
Q2
$41.5K Sell
13,923
-3,894
-22% -$10.8K ﹤0.01% 3355
2024
Q1
$61.5K Buy
+17,817
New +$39.8K ﹤0.01% 3345
2023
Q4
– Sell
-25,070
Closed -$54.7K – 3703
2023
Q3
$54.7K Buy
+25,070
New +$56.6K ﹤0.01% 3389

Other funds holding TRVI

Deutsche Bank's TRVI Position: Q3 2026 in Review

Deutsche Bank reduced its Trevi Therapeutics (TRVI) stake by 6.3% in Q3 2026, selling an estimated $124K and leaving 107,271 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

Deutsche Bank first reported a position in TRVI in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.14M in Q2 2026. 223 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Deutsche Bank held 107,271 shares of Trevi Therapeutics worth $1.54M as of Q3 2026.
  • Deutsche Bank sold 7,216 Trevi Therapeutics shares in Q3 2026, an estimated $124K.
  • Trevi Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #1947 holding.
  • Deutsche Bank first reported a position in Trevi Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Deutsche Bank's Trevi Therapeutics position peaked at $2.14M in Q2 2026.
  • 223 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.